Measuring variability of heart rate may identify premature infants at risk of developing narcotising enterocolitis, a serious inflammatory condition that can lead to death, according to Penn State College of Medicine researchers.

Narcotising enterocolitis, or NEC, may lead to destruction of the intestinal wall and vital organ failure. It affects 6 to 10 percent of premature infants within the first two weeks of life.

‘NEC is currently diagnosed by a combination of laboratory and radiology tests, usually done when the disease is already significant,’ said Kim Doheny, director of clinical research in newborn medicine and assistant professor of pediatrics. ‘Since NEC progresses so rapidly and the symptoms develop suddenly, a non-invasive biomarker that allows early detection of patients at risk is required as a matter of urgency.’

Heart rate fluctuates in the intervals between beats, and contributors to this fluctuation are measured through mathematical analysis. One of these contributors is the parasympathetic nervous system — the system that controls digestive responses and regulates the organs during rest — represented through measurement of high-frequency energy distribution. The researchers studied 70 infants born at 28 to 35 weeks within the first five to eight days of life. The babies were stable with no sign of illness.

The researchers then measured heart rate variability in the infants to test whether measuring the high-frequency component of heart rate variability may be used as a way to predict an infant’s NEC risk before disease onset.

Of the 70 infants studied, nine who later developed NEC had decreased high frequency in the heart rate variability, suggesting reduced parasympathetic nervous system activity. Of all the infants with a decreased high-frequency heart rate variability, 50 percent developed the disease. In contrast, 98 percent of those with a higher high-frequency value did not get the disease.

‘This shows that measuring high-frequency variability during this early critical window of postnatal development has value for identifying NEC risk at a time when symptoms are not evident and interventions to improve the parasympathetic nervous system activity can be given,’ said researcher R. Alberto Travagli, professor of neural and behavioral sciences. ‘This relatively simple, economical, and non-invasive method offers the opportunity to monitor at-risk infants more closely and to test the efficacy of emerging treatments.’

The researchers say future investigations should include a larger sample that also includes measurement of inflammation at the time heart rate variability is measured. Penn State College of Medicine

For the millions of people forced to rely on a plastic tube to eliminate their urine, developing an infection is nearly a 100 percent guarantee after just four weeks. But with the help of a little bubble-blowing, biomedical engineers hope to bring relief to urethras everywhere.
About half of the time, the interior of long-term urinary catheters become plagued by biofilms

Researchers at the University of British Columbia have identified a small molecule that prevents bacteria from forming into biofilms, a frequent cause of infections. The anti-biofilm peptide works on a range of bacteria including many that cannot be treated by antibiotics.

‘Currently there is a severe problem with antibiotic-resistant organisms,’ says Bob Hancock, a professor in UBC

When a person suffers a broken bone, treatment calls for the surgeon to insert screws and plates to help bond the broken sections and enable the fracture to heal. These ‘fixation devices’ are usually made of metal alloys.

But metal devices may have disadvantages: Because they are stiff and unyielding, they can cause stress to underlying bone. They also pose an increased risk of infection and poor wound healing. In some cases, the metal implants must be removed following fracture healing, necessitating a second surgery. Resorbable fixation devices, made of synthetic polymers, avoid some of these problems but may pose a risk of inflammatory reactions and are difficult to implant.

Now, using pure silk protein derived from silkworm cocoons, a team of investigators from Tufts University School of Engineering and Beth Israel Deaconess Medical Center (BIDMC) has developed surgical plates and screws that may not only offer improved bone remodelling following injury, but importantly, can also be absorbed by the body over time, eliminating the need for surgical removal of the devices.
‘Unlike metal, the composition of silk protein may be similar to bone composition,’ says co-senior author Samuel Lin, MD, of the Division of Plastic and Reconstructive Surgery at BIDMC and Associate Professor of Surgery at Harvard Medical School. ‘Silk materials are extremely robust. They maintain structural stability under very high temperatures and withstand other extreme conditions, and they can be readily sterilised.’

Collaborating with Lin were co-senior author and Tufts chair of biomedical engineering David Kaplan, PhD, a leader in the use of silk for biomedical applications, and a team of biomedical and mechanical engineers.

‘One of the other big advantages of silk is that it can stabilise and deliver bioactive components, so that plates and screws made of silk could actually deliver antibiotics to prevent infection, pharmaceuticals to enhance bone regrowth and other therapeutics to support healing,’ says Kaplan.

Kaplan and his team have previously developed silk-based sponges, fibres and foams for use in the operating room and in clinical settings. But until now, silk hadn

A new way to artificially control muscles using light, with the potential to restore function to muscles paralysed by conditions such as motor neuron disease and spinal cord injury, has been developed by scientists at UCL and King